Clinical Trial Update: Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors:

View source ↗

Summary

A breast cancer adjuvant trial evaluating a CDK4/6 inhibitor is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CDK4/6 inhibitor (class)

Snippet

Sponsor: European Institute of Oncology | Conditions: Adjuvant Therapy, CDK4/6 Inhibitor | Status: RECRUITING